Understand the source comparison
The Blunt Truth About ARA-290 vs VIP
Here's the honest answer: this comparison exists because both peptides get labeled 'neuroprotective' in supplier catalogs, but the mechanisms couldn't be more different. ARA-290 is a designer peptide engineered to isolate one specific pathway from erythropoiet
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's the honest answer: this comparison exists because both peptides get labeled 'neuroprotective' in supplier catalogs, but the mechanisms couldn't be more different. ARA-290 is a designer peptide engineered to isolate one specific pathway from erythropoietin. Tissue protection without hematopoiesis. VIP is an endogenous signaling molecule with functions spanning digestion, immune regulation, circadian rhythm, and vasodilation. Calling it a 'neuroprotective peptide' undersells its systemic reach. Researchers who select peptides based on generic category labels rather than receptor specificity end up with mismatched compounds that don't address their experimental question. The decision framework is straightforward: if your research objective involves T-cell modulation, autoimmune suppression, or systemic inflammation, VIP is the compound. If you're studying direct cellular protection in a specific tissue after ischemic, metabolic, or toxic injury, ARA-290 is the compound. The peptide
- ARA-290's clinical trial data in peripheral neuropathy gives it an edge in nerve regeneration research, but that advantage disappears entirely in immune-mediated disease models where VIP's Treg-promoting effects are the relevant mechanism. Conversely, VIP's broad VPAC receptor distribution creates systemic effects that may be unwanted in studies requiring isolated tissue-level intervention. Contexts where ARA-290's selective CD131 binding prevents off-target immune suppression. We've reviewed procurement patterns across research institutions in immunology, cardiology, and neurology departments. The pattern is consistent: labs working on autoimmune models stock VIP; labs studying ischemic injury or diabetic complications stock ARA-290. The rare lab that maintains both is usually running head-to-head mechanistic studies comparing inflammatory suppression versus direct cytoprotection. And those studies consistently show the peptides don't substitute for one another.
- Neither peptide is inherently superior. Mechanism determines selection, period. Researchers treating these compounds as interchangeable alternatives are operating from incomplete understanding of receptor biology. At Real Peptides, every peptide in our catalog is synthesized with exact amino-acid sequencing because precision matters when biological activity depends on receptor binding specificity. A principle that applies as much to peptide selection as it does to synthesis quality.
- The decision between ARA-290 and VIP isn't about which peptide is 'better'. It's about which receptor system your research question actually requires. Match the mechanism to the model, and the choice becomes obvious.